Sensorion is a pioneering clinical-stage company dedicated to developing innovative therapies to restore, treat and prevent inner-ear pathologies such as deafness, vertigo and tinnitus.
They are developing treatments that could revolutionize the management of patients suffering from inner ear disorders
Two products are in Phase 2 clinical development: Séliforant (SENS-111) in acute unilateral vestibulopathy and Arazasetron (SENS-401) in acute sensorineural hearing loss (SSNHL).
Sensorion’s laboratories have developed a unique R&D platform to deepen understanding of the pathophysiology and etiology of inner ear diseases, in order to select the best therapeutic targets and appropriate mechanisms of action for our drug candidates. They are also working on the identification of biomarkers to improve the diagnosis and treatment of these poorly treated diseases. Their R&D platform and portfolio of drug candidates uniquely position them to make a lasting improvement to the quality of life of the hundreds of thousands of people suffering from inner ear disorders.
a largely unmet medical need in the world today.
